StreetInsider.com News Articles

Form 8-K Tvardi Therapeutics, For: Jul 30

Thu, 30 Jul 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260730/26838832.html

Form 8-K Tvardi Therapeutics, For: Jul 30

Thu, 30 Jul 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260730/26838832.html

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

Thu, 30 Jul 2026 07:30:00 -0400

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling

More than 70% of patients do not achieve clinical remission with currently approved UC therapies, which target individual upstream pathways; TTI-109 is designed to directly inhibit STAT3 where these pathways intersect

Selection follows completion of the TTI-109 Phase 1 healthy volunteer study, which demonstrated placebo-adjusted reductions across cellular and humoral immune cell subsets implicated in UC pathology

Company to host KOL webinar with Dr. Randy Longman, M.D., Ph.D. on Wednesday,

Form 8-K Tvardi Therapeutics, For: Jul 17

Fri, 17 Jul 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260717/26784403.html

Form 8-K Tvardi Therapeutics, For: Jul 17

Fri, 17 Jul 2026 16:08:00 -0400
si-local-file:///var/storage/secattach/20260717/26784403.html

Form 424B5 Tvardi Therapeutics,

Fri, 17 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260717/26784354.html

Form 424B5 Tvardi Therapeutics,

Fri, 17 Jul 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260717/26784354.html

Piper Sandler Upgrades Tvardi Therapeutics Inc (TVRD) to Overweight

Wed, 08 Jul 2026 15:38:54 -0400

Piper Sandler analyst Yasmeen Rahimi upgraded Tvardi Therapeutics Inc (NASDAQ: TVRD) from Neutral to Overweight with a price target of $13.00 (from $3.00).
For an analyst ratings summary and ratings history on Tvardi Therapeutics Inc click here. For more ratings news on Tvardi Therapeutics Inc click here.
Shares of Tvardi Therapeutics Inc closed at $3.10 yesterday.

Raymond James Upgrades Tvardi Therapeutics Inc (TVRD) to Outperform

Wed, 08 Jul 2026 03:47:58 -0400

Raymond James analyst Ryan Deschner upgraded Tvardi Therapeutics Inc (NASDAQ: TVRD) from Market Perform to Outperform with a price target of $10.00.
The analyst comments: “We are upgrading TVRD to Outperform after the recently reported Phase 1 dataset for STAT3 inhibitor prodrug, TTI-109, showed evidence of placebo-like GI tolerability, general bioequivalence with TTI-101 in terms of dose-proportional exposure above the IC50 of STAT3, and substantial reductions in humoral and cellular immune populations across the explored active dosing range. TVRD is now pivoting away from IPF to one or more target indications in the GI and dermatology spaces, which, pending additional funding,

Raymond James Upgrades Tvardi Therapeutics Inc (TVRD) to Outperform

Wed, 08 Jul 2026 03:47:58 -0400

Raymond James analyst Ryan Deschner upgraded Tvardi Therapeutics Inc (NASDAQ: TVRD) from Market Perform to Outperform with a price target of $10.00.
The analyst comments: “We are upgrading TVRD to Outperform after the recently reported Phase 1 dataset for STAT3 inhibitor prodrug, TTI-109, showed evidence of placebo-like GI tolerability, general bioequivalence with TTI-101 in terms of dose-proportional exposure above the IC50 of STAT3, and substantial reductions in humoral and cellular immune populations across the explored active dosing range. TVRD is now pivoting away from IPF to one or more target indications in the GI and dermatology spaces, which, pending additional funding,